Marvel Biosciences reports preliminary MB-204 positive Shank3 ASD results

The company said preliminary preclinical results from MB-204 in the Shank3Δex13-16 mouse model showed improvements in multiple autism-related behaviors and outperformed istradefylline at tested doses, with full statistics pending.